<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01718951</url>
  </required_header>
  <id_info>
    <org_study_id>CREC/769/09</org_study_id>
    <nct_id>NCT01718951</nct_id>
  </id_info>
  <brief_title>Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial</brief_title>
  <official_title>Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of golimumab with pamidronate in the treatment of axial
      spondyloarthropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of golimumab with pamidronate in the treatment of non-radiological
      axial spondyloarthropathy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response response</measure>
    <time_frame>week 48</time_frame>
    <description>Proportion of patients who achieve the Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI spinal inflammation scores</measure>
    <time_frame>week 24 and 48</time_frame>
    <description>Changes in MRI spinal inflammation scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Spondyloarthropathy</condition>
  <arm_group>
    <arm_group_label>golimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>golimumab 50mg subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pamidronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pamidronate (60mg) intravenously every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>golimumab</intervention_name>
    <description>golimumab</description>
    <arm_group_label>golimumab</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>pamidronate</description>
    <arm_group_label>pamidronate</arm_group_label>
    <other_name>Aridia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects greater than 18 years of age

          2. Fulfilling the latest classification criteria for axial spondyloarthropathy

          3. Active spondylitis as defined by a Bath Ankylosing Spondylitis Disease Activity Index
             (BASDAI) score of more than 4 despite treatment with non-steroid anti-inflammatory
             drugs for more than 3 months

        Exclusion Criteria:

          1. Major surgery (including joint surgery) within 8 weeks prior to study entry

          2. History of treatment with anti-tumor necrosis factor agents or any investigational
             therapies within 12 months of study entry

          3. Immunization with a live/attenuated vaccine within 4 weeks prior to study entry

          4. Active current bacterial, viral, fungal, mycobacterial or other infections at study
             entry

          5. Chronic hepatitis B or hepatitis C carriers

          6. History of malignancies, including solid tumors and hemic malignancies

          7. History of congestive heart failure

          8. History of demyelinating disorders

          9. History of peripheral neuropathy

         10. Pregnant women or lactating mothers

         11. Baseline liver parenchymal enzymes elevated to more than 2 times normal

         12. Absolute lymphocyte count less than 500/mm3

         13. Serum creatinine level of more than 200umol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tuen Mun Hospital</investigator_affiliation>
    <investigator_full_name>Chi Chiu Mok</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>spondyloarthropathy</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthropathies</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

